FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247195017> ?p ?o ?g. }

• W2247195017 abstract "15110 Background: GNET represent an unusual family of neoplasms with a wide and complex spectrum of clinical behavior. To provide information regarding demographic characteristics, diagnostic procedures, tumor features, therapeutic interventions and outcomes of pts with GNETs, a national tumor registry was launched. We present here the results of this broad-based multi-institutional observational registry that comprises 41 sites representing all regions of Spain. Methods: Data was provided at www.retegep.net by participating centers and assessed for internal consistency by external independent reviewers. Results: The study cohort comprised 474 pts (57% male, median age: 59 years). 52% were carcinoids (C), 18% non-functioning pancreatic tumors (PT), 9% insulinomas and 6% gastrinomas. Most common primary tumor sites included midgut (19%), and head (14%) and body of the pancreas (9%). 10% were of unknown primary. Functioning symptoms led to diagnosis in 29% of cases. 5% were associated to MEN1. Diagnostic workup included serum hormone tests (60%), ultrasound (40%), CT scan (75%) and octreoscan (37%). 32% of pts presented with localized tumors (L), 14% with local-regional spread (LR) and 44% with advanced disease (Adv). Treatment for Adv disease consisted of somatostatin analogues (SA) (48%), surgery (45%), chemotherapy (CT) (42%), interferon (IFN) (23%), chemoembolization (9%) and radiofrequency ablation (5%). 5-year survival (5yS) for the whole group was 61.1% (SD:3.4%), 78.2% (SD:5.4%) for pts with L/LR disease and 47.1% (SD:5.6%) for Adv stages. 5yS rates were similar for C and PT tumors, also when stratifying according to tumor stage (84 and 76% for local-regional disease, and 51 and 49% for Adv disease). 1 st line systemic therapy (n=175) consisted of CT (42%), SA (39%), IFN (5%), SA+IFN (10%) and SA+CT (3%), with 5yS rates of 59%, 36%, 42%, 46% and 38%, respectively (p=0.7). As second line systemic treatment (n=65) 45% received CT, 26% SA, 15% immunotherapy and 14% different drug combinations. Conclusions: This national database reveals relevant information regarding current Spanish practices and will provide valuable insights into the epidemiology and management of this heterogeneous uncommon disease No significant financial relationships to disclose." @default.
• W2247195017 created "2016-06-24" @default.
• W2247195017 creator A5021910247 @default.
• W2247195017 creator A5023000031 @default.
• W2247195017 creator A5024147987 @default.
• W2247195017 creator A5035175323 @default.
• W2247195017 creator A5048223620 @default.
• W2247195017 creator A5053949603 @default.
• W2247195017 creator A5057373704 @default.
• W2247195017 creator A5072522859 @default.
• W2247195017 creator A5078401635 @default.
• W2247195017 creator A5085476251 @default.
• W2247195017 date "2007-06-20" @default.
• W2247195017 modified "2023-10-17" @default.
• W2247195017 title "Patterns of care and outcome of patients with gastroenteropancreatic neuroendocrine tumors (GNETs): Results from a Spanish multi-center hospital-based tumor registry" @default.
• W2247195017 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15110" @default.
• W2247195017 hasPublicationYear "2007" @default.
• W2247195017 type Work @default.
• W2247195017 sameAs 2247195017 @default.
• W2247195017 citedByCount "0" @default.
• W2247195017 crossrefType "journal-article" @default.
• W2247195017 hasAuthorship W2247195017A5021910247 @default.
• W2247195017 hasAuthorship W2247195017A5023000031 @default.
• W2247195017 hasAuthorship W2247195017A5024147987 @default.
• W2247195017 hasAuthorship W2247195017A5035175323 @default.
• W2247195017 hasAuthorship W2247195017A5048223620 @default.
• W2247195017 hasAuthorship W2247195017A5053949603 @default.
• W2247195017 hasAuthorship W2247195017A5057373704 @default.
• W2247195017 hasAuthorship W2247195017A5072522859 @default.
• W2247195017 hasAuthorship W2247195017A5078401635 @default.
• W2247195017 hasAuthorship W2247195017A5085476251 @default.
• W2247195017 hasConcept C126322002 @default.
• W2247195017 hasConcept C126838900 @default.
• W2247195017 hasConcept C143998085 @default.
• W2247195017 hasConcept C2779066768 @default.
• W2247195017 hasConcept C71924100 @default.
• W2247195017 hasConcept C72563966 @default.
• W2247195017 hasConcept C90924648 @default.
• W2247195017 hasConceptScore W2247195017C126322002 @default.
• W2247195017 hasConceptScore W2247195017C126838900 @default.
• W2247195017 hasConceptScore W2247195017C143998085 @default.
• W2247195017 hasConceptScore W2247195017C2779066768 @default.
• W2247195017 hasConceptScore W2247195017C71924100 @default.
• W2247195017 hasConceptScore W2247195017C72563966 @default.
• W2247195017 hasConceptScore W2247195017C90924648 @default.
• W2247195017 hasLocation W22471950171 @default.
• W2247195017 hasOpenAccess W2247195017 @default.
• W2247195017 hasPrimaryLocation W22471950171 @default.
• W2247195017 hasRelatedWork W2049214470 @default.
• W2247195017 hasRelatedWork W2315085516 @default.
• W2247195017 hasRelatedWork W2316407790 @default.
• W2247195017 hasRelatedWork W2329989313 @default.
• W2247195017 hasRelatedWork W2584020663 @default.
• W2247195017 hasRelatedWork W2603773853 @default.
• W2247195017 hasRelatedWork W2902148150 @default.
• W2247195017 hasRelatedWork W2964295425 @default.
• W2247195017 hasRelatedWork W4220960064 @default.
• W2247195017 hasRelatedWork W4307502331 @default.
• W2247195017 isParatext "false" @default.
• W2247195017 isRetracted "false" @default.
• W2247195017 magId "2247195017" @default.
• W2247195017 workType "article" @default.